MAR 15, 2019 12:41 AM PDT

Vaccine Blocks Osteoarthritis Pain in Mice

WRITTEN BY: Nouran Amin

A virus-like particle vaccine was developed to stop chronic pain caused by osteoarthritis inhibiting a nerve growth factor (NGF). The vaccine was administered in mice who exhibited symptoms of painful osteoarthritis and was shown to visibly reverse these effects. The vaccine works by triggering the immune system to produce antibodies to block naturally-occurring NGF. “I’m happy to see the vaccine platform perform so well, and look forward to seeing the vaccine enter clinical testing in companion animals,” said co-lead author Professor Martin Bachmann, from the Jenner Institute at the University of Oxford and the University of Bern.

Pain in osteoarthritis poses a substantial social and economic burden with fewer than 25% of patients having adequate pain control. NGF has emerged as a key driver of pain behavior in murine studies and antibodies to NGF are potent analgesics in human osteoarthritis. Using a novel virus-like particle, von Loga et al created a therapeutic vaccine that reversibly induced antibodies against NGF and abrogated pain behavior in murine osteoarthritis.

Image credit: OpenStax / CC BY 4.0.

“This is the first successful vaccination to target pain in osteoarthritis, one of the biggest healthcare challenges of our generation,” said co-lead author Professor Tonia Vincent, a researcher at the Kennedy Institute of Rheumatology at the University of Oxford.“Whilst there are still safety issues that need to be considered before these types of approaches can be used in patients, we are reassured that this vaccine design allows us to control antibody levels and thus tailor treatment to individual cases according to need.”

Current pain relief therapeutics for osteoarthritis include NSAID’s and opioids. However, NGF is a promising target for osteoarthritis pain.

“Too many people living with pain do not get effective relief from the treatments that are currently available, and that is why the development of more effective painkillers, with fewer side-effects, is vital for people living with arthritis,” said Dr. Stephen Simpson, Director of research at Versus Arthritis, which funded the study. “Although at an early stage, this is highly innovative research and these results are very promising.”

Findings of the study were published in Annals of Rheumatic Disease.

Source: Sci-News

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 18, 2020
Cancer
APR 18, 2020
A New Double Threat Against Skin Cancer
Skin cancer is one of the most common cancers in America.  One of the most aggressive forms of cancer is melanoma, ...
APR 30, 2020
Drug Discovery & Development
APR 30, 2020
Shortcuts in Drug Development may Cause Long Term Damage
   
MAY 09, 2020
Cancer
MAY 09, 2020
Examining a Combination Therapy Against Gastric Cancer
Often when it comes to treatments for cancer, designing or discovering new leads can take years. One of the common pract ...
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
MAY 23, 2020
Cancer
MAY 23, 2020
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Approved Treatment for RET-mutant Cancers
A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) ad ...
Loading Comments...